Changes to legislation: There are outstanding changes not yet made to Commission Regulation (EU) No 1154/2014. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

ANNEX

REJECTED HEALTH CLAIMS

| Application — Relevant provisions of Regulation (EC) No 1924/2006 | Nutrient, substance, food or food category | Claim | EFSA opinion reference |
|---|--|---|---------------------------|
| Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data | Zinc | Prevents bad breath by neutralising of volatile sulphur compounds (VSC) in the mouth and oral cavity. | Q-2010-01092 |
| Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data | Yestimun® | Daily administration of Yestimun® helps to maintain the body's defence against pathogens. | Q-2012-00761 |
| Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data | Transitech® | Improves transit and durably regulates it. | Q-2013-00087 |
| Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data | Bimuno® GOS | Regular daily consumption of 1,37 g galacto- oligosaccharides from Bimuno® may reduce abdominal discomfort. | Q-2012-01007 |
| Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data | <i>Lactobacillus rhamnosus</i> GG | <i>Lactobacillus</i> <i>rhamnosus</i> GG for maintaining normal defecation during oral antibiotic treatment. | Q-2013-00015 |
| Article 13(5) health claim based on newly developed scientific evidence and/or including a request | VeriSol®P | Characteristic collagen peptide mixture (collagen hydrolysate) having a beneficial physiological effect | Q-2012-00839 |

Changes to legislation: There are outstanding changes not yet made to Commission Regulation (EU) No 1154/2014. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

| for the protection of proprietary data | | on the maintenance of skin health, as indicated by an increased skin elasticity and a reduction of wrinkles volume, by contributing to a normal collagen and elastin synthesis. | |
|---|--------------------------------|---|--------------|
| Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data | Proanthocyanidins in Urell® | Proanthocyanidins from Urell® contribute to support defence against bacterial pathogens in the lower urinary tract | Q-2012-00700 |
| Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data | Preservation® | Improves the physiological response to stress by accelerating the appearance of heat shock proteins (HSPs) and maintains an effective level of HSPs to ensure that the organism is primed should the cell encounter further stress. | Q-2013-00021 |

Changes to legislation:

There are outstanding changes not yet made to Commission Regulation (EU) No 1154/2014. Any changes that have already been made to the legislation appear in the content and are referenced with annotations.

View outstanding changes

Changes and effects yet to be applied to :

- Art. 1 word omitted by S.I. 2019/651 reg. 58(2)(a)
- Art. 1 words substituted by S.I. 2019/651 reg. 58(2)(b)
- Art. 1(2) omitted by S.I. 2019/651 reg. 58(2)(c)
- Art. 2 omitted by S.I. 2019/651 reg. 58(3)